Hypothalamic Nitric Oxide Signaling for PCOS Sexual Dysfunction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Polycystic ovary syndrome (PCOS) is associated with significant sexual dysfunctions, including low sexual arousal, desire, and satisfaction, due to disturbances in brain circuits controlling sexual function, which are not adequately addressed by current treatments.

Innovation Solution

Administration of Nitric Oxide (NO) agents, such as inhaled NO or NO donors, to restore normal sexual behavior by replenishing NO expression in hypothalamic regions affected by PCOS, such as the rostral periventricular area of the third ventricle, ventromedial nucleus of the hypothalamus, and arcuate nucleus.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments are used for PCOS, then general symptoms may be managed, but sexual dysfunction remains inadequately addressed

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidsexual dysfunction

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces nitric oxide (NO) as an intermediary substance to restore neural communication in the hypothalamic circuits. NO acts as a gaseous neurotransmitter that mediates between the disrupted neural pathways, facilitating restored sexual behavior without directly addressing the underlying PCOS pathology. This mediator approach allows treatment of the specific sexual dysfunction symptom while the patient remains diagnosed with PCOS.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The treatment involves changing the chemical parameter of nitric oxide availability in the hypothalamic region. By administering NO donors or precursors, the patent alters the concentration and activity of NO in specific brain circuits, thereby restoring normal sexual behavior parameters without changing the overall PCOS diagnostic criteria or other systemic parameters.

Inventive Principle:

Principle #35Parameter changes

2Ease of operation

If NO agents are administered to restore sexual behavior, then sexual function improves, but the underlying PCOS pathology remains

Engineering Contradiction:

Improvesexual behaviorVSAvoidpathology resolution

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent extracts the sexual dysfunction component from the overall PCOS syndrome for targeted treatment. By specifically addressing the nitric oxide deficiency in hypothalamic circuits responsible for sexual behavior, the treatment isolates and treats this particular symptom without attempting to resolve the entire PCOS pathology, allowing improved ease of sexual operation while acknowledging persistent underlying disease.

Inventive Principle:

Principle #2Taking out (Extraction)

3Stability of the object's composition

If prenatal AMH excess causes neural reprogramming, then PCOS traits develop, but sexual circuit dysfunction occurs

Engineering Contradiction:

Improveneural circuit architectureVSAvoidsexual circuit dysfunction

Core Design Contradiction:

Stability of the object's compositionVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary compensatory action by administering nitric oxide agents to counteract the prenatal reprogramming effects. Rather than attempting to reverse the established neural changes from prenatal AMH excess, the treatment proactively introduces NO to establish functional compensation in the affected hypothalamic circuits, restoring sexual behavior despite the stable but altered neural architecture.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

NO agents effectively restore normal sexual behavior in PCOS-like mice by normalizing neuronal activation in hypothalamic and limbic structures, suggesting potential therapeutic benefits for PCOS-related sexual dysfunctions and hypoactive sexual desire disorder (HSDD).

Implementation Method 1

The VMH harbors neurons expressing the neuronal nitric oxide synthase (nNOS), the enzyme responsible for the production of nitric oxide (NO), a key gaseous neurotransmitter that stimulates female sexual behavior

Methodology Applied

Scientific EffectNitric oxide signaling:

Data Source

PatentUS20250288607A1Methods for treating sexual dysfunction associated with polycystic ovary syndrome (PCOS) or with hypoactive sexual desire disorder (HSDD)

Publication Date: 2025.09.18 INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)

AI summary

In the present invention, inventors demonstrate that prenatal excess of anti-Müllerian hormone triggers PCOS-like impairment in female sexual behavior in mice. Sexual dysfunction in PCOS-like mice is associated with decreased expression of neuronal nitric oxide synthase (nNOS) neurons in different hypothalamic regions known to be involved in female sexual behavior: rostral periventricular area of the third ventricle (RP3V), ventromedial nucleus of the hypothalamus (VMH), and arcuate nucleus (ARN) during estrus. Chemogenetic inhibition of nNOS neuronal activity in the ventromedial nucleus of the hypothalamus of control adult females recapitulates PCOS-like sexual dysfunction. Of clinical relevance, administration of nitric oxide (NO) donor rescues normal sexual behavior in PCOS-like mice. Accordingly, the present invention relates to invention relates to Nitric Oxyde (NO) agent for use in the prevention or the treatment of sexual dysfunction associated with Polycystic Ovary Syndrome (PCOS) or with Hypoactive Sexual Desire Disorder (HSDD) in a subject in need thereof.